SS-31 (Elamipretide)
elamipretidebendaviamtp-131
Cardiolipin-binding tetrapeptide. Mitochondrial-disease research; clinical-trial markers.
- Half-life
- 2.5 h
- Out of system
- ~13 h
- Route
- Subcutaneous
- Level
- Advanced
Short-acting — protocols usually dose daily. After the last dose, roughly 97% has cleared in ~13 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What SS-31 (Elamipretide) is used for
- Cardiolipin-binding tetrapeptide — mitochondrial function
- In clinical trials for mitochondrial disease
How it's typically used
Trial range: ~40 mg subcutaneous daily.
What to watch for
- Benefit in healthy adults is unproven
- Still investigational
- Research-only outside trials
About Longevity
- What they are
- Compounds studied for cellular ageing — mitochondrial function, senescent-cell clearance, telomere and autophagy pathways.
- How they're run
- Mixed routes: some injected in short annual or biannual courses, others taken orally every day.
- What to watch
- Endpoints here are measured in decades, so nobody has human outcome data. Bloodwork and function markers are the only feedback you will get in a realistic timeframe.
Full guide
SS-31 (Elamipretide): Tracking a Mitochondria-Targeting Tetrapeptide
A tracking guide for SS-31/elamipretide, the cardiolipin-binding peptide studied in mitochondrial disease and heart failure.
Other longevity
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.